Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP

OBJECTIVE: Human T‐cell lymphotropic virus 1 (HTLV‐1)‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a chronic, progressive myelopathy. A high proviral load (PVL) is one of the main risk factors for HAM/TSP. Recently, it was shown that raltegravir could inhibit cell‐free and cell‐to...

Descripción completa

Detalles Bibliográficos
Autores principales: Enose‐Akahata, Yoshimi, Billioux, Bridgette Jeanne, Azodi, Shila, Dwyer, Jennifer, Vellucci, Ashley, Ngouth, Nyater, Nozuma, Satoshi, Massoud, Raya, Cortese, Irene, Ohayon, Joan, Jacobson, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528465/
https://www.ncbi.nlm.nih.gov/pubmed/34562313
http://dx.doi.org/10.1002/acn3.51437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8528465/
https://www.ncbi.nlm.nih.gov/pubmed/34562313
http://dx.doi.org/10.1002/acn3.51437

Ejemplares similares